跳到正文
原文
MedPage Today·· 4 天前精选AI 评分80

GLP-1受体拮抗剂在术后低血糖中的临床意义

GLP-1 Antagonist Shows Clinically Meaningful Results in Post-Bariatric Hypoglycemia

AI 导读

LUCIDITY三期临床试验显示,GLP-1受体拮抗剂avexitide显著减少术后低血糖事件,降低54%。研究支持GLP-1受体信号在术后低血糖中的关键作用,为新疗法提供了证据。

推荐理由

研究显示GLP-1受体拮抗剂显著减少术后糖尿病低血糖事件,为治疗提供新方向。

正文

— LUCIDITY trial supports GLP-1 receptor signaling as a central driver of PBH pathophysiology

November 16, 2026 • 3 min read

NATIONAL HARBOR, Md. -- An investigational first-in-class GLP-1 receptor antagonist significantly reduced hypoglycemic events after bariatric surgery in the phase III LUCIDITY trial.

From a baseline mean of 2.39 events per week among patients with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass surgery, the weekly rate of composite level 2 and 3 hypoglycemic events dropped to 0.55 with once-daily avexitide versus 1.24 with placebo at week 16 (rate ratio [RR] 0.45, 95% CI 0.32-0.63, P=0.0000034), reported Marilyn Tan, MD, of Stanford University School of Medicine in California, at the ObesityWeek annual meeting.

Level 2 hypoglycemia was defined as a blood glucose level below 54 mg/dL (when neuroglycopenic symptoms begin), and level 3 was defined as altered mental or physical function requiring external assistance for recovery.

All prespecified secondary endpoints also met statistical significance, with consistent results across sensitivity analyses and subgroups.

The findings support GLP-1 receptor signaling as a central driver in PBH pathophysiology, noted Tan.

"After bariatric surgery, there is altered nutrient transit, which leads to enhanced intestinal L-cell activation," she explained. "PBH is a chronic metabolic condition characterized by an exaggerated postprandial GLP-1 response, which leads to excessive insulin secretion and hyperinsulinemic hypoglycemia, typically occurring 1 to 3 hours after meals and often developing months to years after surgery."

While prevalence has historically been difficult to pinpoint, current estimates suggest roughly 12% of Roux-en-Y gastric bypass patients and 5% of sleeve gastrectomy patients develop PBH requiring medical management, Tan said.

There are currently no FDA-approved therapies specifically indicated for PBH, leaving patients to rely on dietary modification and off-label medications. The condition carries a heavy clinical burden, Tan noted, pointing to a recent survey in which more than 90% of respondents with PBH considered themselves functionally disabled.

The double-blind LUCIDITY trial enrolled 78 adults who experienced at least two hypoglycemic events per week during a 21-day run-in period while following strict dietary management. Participants were randomized 3:2 to subcutaneous avexitide 90 mg once daily or placebo for 16 weeks alongside continued medical nutrition therapy, which restricted intake of carbohydrates to 30 g or less per meal and 15 g or less per snack, emphasized adequate protein, and avoided simple sugars.

"We provided these patients with the gold standard of care," Tan pointed out, including regular dietary check-ins, structured nutrition therapy, unlimited blood sugar testing supplies, and continuous glucose monitors (CGMs) with safety alarms. "The reality is that many patients living with this disease do not have this level of access to healthcare. Even in this highly supported environment, avexitide still significantly reduced hypoglycemic events beyond placebo."

At baseline, mean participant age was 50.8, 96% were women, mean body mass index was 28.3, and mean weight loss since surgery was 99 lb. Most patients (68%) experienced daily hypoglycemia symptoms, 47% had a history of losing consciousness, and 28% had a prior PBH-related hospitalization.

As noted above, all three secondary endpoints also favored avexitide versus placebo:

  • Level 2 hypoglycemic events measured by self-monitoring of blood glucose: RR 0.37 (95% CI 0.24-0.56, P=0.0000032)
  • Level 2 hypoglycemic events measured by CGM: RR 0.58 (95% CI 0.43-0.77, P=0.00016)
  • Level 3 hypoglycemic events measured by an event adjudication committee: RR 0.53 (95% CI 0.36-0.79, P=0.0016)

Treatment-emergent adverse events (AE) were mild to moderate and primarily gastrointestinal or injection-site related, most commonly diarrhea, injection-site erythema, and injection-site bruising. Two patients in the avexitide arm and one in the placebo arm discontinued treatment due to AEs, and no deaths or treatment-related serious AEs occurred.

There were no clinically meaningful changes in body weight (+0.8 kg with avexitide vs +1.5 kg with placebo) or fasting plasma glucose (+3.1 vs +2.8 mg/dL). Nearly all patients on avexitide (91.3%) maintained a body weight within 5% of baseline or lower, compared with 75% on placebo.

LUCIDITY's 32-week open-label extension remains ongoing. Developer Amylyx Pharmaceuticals plans to submit a new drug application to the FDA by the end of the year, ahead of a potential 2027 launch.

来源:MedPage Today · medpagetoday.com